ArticleScience translational medicine2022
Therapeutic efficacy of antimalarial drugs targeting DosRS signaling in
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Efficacy of regimens targeting Mycobacterium abscessus in vitro and in vivo.BMC microbiology · 2026Article
- Contribution of Proteins to Membrane and Cell Wall Structures in Mycobacterium tuberculosis.Advances in experimental medicine and biology · 2026Review
- In vitro and in silico evaluation of fluorinated diphenylamine chalcone derivatives as potential antimalarial and anticancer agents.Scientific reports · 2025Article
- A Simple In Vitro Method to Determine Bactericidal Activity AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Activity of combinations of bactericidal and bacteriostatic compounds inFrontiers in microbiology · 2025Review
- Exploration of innovative drug repurposing strategies for combating human protozoan diseases: Advances, challenges, and opportunities.Journal of pharmaceutical analysis · 2025Review
- The DosR regulon ofFrontiers in cellular and infection microbiology · 2025Article
- Loss of glycerol catabolism confers carbon-source-dependent artemisinin resistance inAntimicrobial agents and chemotherapy · 2024Article
- Preclinical murine models for the testing of antimicrobials against Mycobacterium abscessus pulmonary infections: Current practices and recommendations.Tuberculosis (Edinburgh, Scotland) · 2024Review
- [Research Trends in Nontuberculous Mycobacterial Treatment].Jugan geon-gang gwa jilbyeong · 2024Review
- Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.Nature reviews. Drug discovery · 2024Review
- Nitric oxide-releasing prodrug for the treatment of complexAntimicrobial agents and chemotherapy · 2024Article
- Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products.Current topics in medicinal chemistry · 2024Review
- A laboratory perspective onFrontiers in microbiology · 2024Review
- Orphan response regulator NnaR is critical for nitrate and nitrite assimilation inFrontiers in cellular and infection microbiology · 2024Article
- Clinically relevant mutations in the PhoR sensor kinase of host-adaptedMicrobiology spectrum · 2023Article
- Targeted Chromosomal Barcoding Establishes Direct Genotype-Phenotype Associations for Antibiotic Resistance in Mycobacterium abscessus.Microbiology spectrum · 2023Article
- Biotin-dependent cell envelope remodelling is required for Mycobacterium abscessus survival in lung infection.Nature microbiology · 2023Article
- Article
- Why Matter Matters: Fast-TrackingMolecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 8 institutions in 3 countries.
Juan Manuel BelardinelliMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.ORCID 0000-0003-1336-9141
Deepshikha VermaMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.ORCID 0000-0002-8549-6409
Wei LiMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
Charlotte AvanziMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.ORCID 0000-0002-1062-4058
Crystal J WiersmaMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
John T WilliamsDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI, USA.ORCID 0000-0002-2742-1636
Benjamin K JohnsonDepartment of Epigenetics, Van Andel Institute, Grand Rapids, MI, USA.ORCID 0000-0002-1482-1032
Matthew ZimmermanCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.ORCID 0000-0002-4390-3555
Nicholas WhittelMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
Bhanupriya AngalaMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
Han WangCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.
Victoria JonesMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
Véronique DartoisCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.ORCID 0000-0001-9470-5009
Vinicius C N de MouraMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
Mercedes Gonzalez-JuarreroMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
Camron PearceMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.ORCID 0000-0002-5091-0331
Alan R SchenkelDepartment of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.ORCID 0000-0002-1603-5713
Kenneth C MalcolmDepartment of Medicine, National Jewish Health, Denver, CO, USA.
Jerry A NickDepartment of Medicine, National Jewish Health, Denver, CO, USA.ORCID 0000-0002-8910-3449
Susan A CharmanCentre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.ORCID 0000-0003-1753-8213
Timothy N C WellsMedicines for Malaria Venture, Geneva, Switzerland.ORCID 0000-0001-9796-847X
Brendan K PodellMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.ORCID 0000-0003-2548-8826
Jonathan L VennerstromCollege of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.ORCID 0000-0003-0075-2336
Diane J OrdwayMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.ORCID 0000-0003-0003-326X
Robert B AbramovitchDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI, USA.ORCID 0000-0002-4119-4169
Mary JacksonMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.ORCID 0000-0002-9212-0258
Colorado State University · USHackensack Meridian Health · USMichigan State University · USNational Jewish Health · USMedicines for Malaria Venture · CHMonash University · AUUniversity of Nebraska Medical Center · USVan Andel Institute · US
Funding
Mechanisms Regulating Megakaryocyte EndomitosisR01HL080442 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAVID, KATYA · 2006 to 2015
$3.6MA QTRAP 6500 LC-MS/MS System from SCIEX for high accuracy drug content analysisS10OD023524 · OD · RBHS-NEW JERSEY MEDICAL SCHOOL · PI DARTOIS, VERONIQUE · 2017 to 2017
$526kZeiss LSM 510 Laser Scanning MicroscopeS10RR023735 · NCRR · COLORADO STATE UNIVERSITY · PI GONZALEZ-JUARRERO, MERCEDES · 2007 to 2007
$437kAdjunct therapeutic potential of a repurposed drug inhibiting Mycobacterium abscessus biofilm formationR21AI147326 · NIAID · COLORADO STATE UNIVERSITY · PI JACKSON, MARY · 2020 to 2021
$418kFluorescence Microscope for Automated Large Array Scanning and 3D imagingS10OD025127 · OD · COLORADO STATE UNIVERSITY · PI BAMBURG, JAMES R · 2018 to 2018
$188kNCRR NIH HHS S10 RR023735NHLBI NIH HHS R01 HL080442NIAID NIH HHS R21 AI147326NIH HHS S10 OD023524NIH HHS S10 OD025127
Abstract
A search for alternative
Indexed as
AntimalarialsMycobacterium abscessusMycobacterium Infections, NontuberculousAnimalsAnti-Bacterial AgentsMiceMicrobial Sensitivity TestsAnti-Bacterial AgentsAntimalarials
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.